Advertisement

Topics

Amgen Reports Results for Repatha in Phase III Cognitive Function Study

10:14 EDT 17 Aug 2017 | Drug Discovery Development

The study demonstrated that Repatha was non-inferior to placebo, with no significant difference in cognitive function between the Repatha and placebo-treated groups.
Contributed Author: 
Topics: 

Original Article: Amgen Reports Results for Repatha in Phase III Cognitive Function Study

NEXT ARTICLE

More From BioPortfolio on "Amgen Reports Results for Repatha in Phase III Cognitive Function Study"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...